Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, France, and India. It operates through Production and Human Health segments. The company manufactures and sells TPM and Vital ET products for use in drug delivery and cosmetic formulations. Its human health portfolio covers delivery of pharmaceutical products through gels, injectables, and patches. In addition, the company develops pharmaceutical products; oral, topical, and edible pharmaceutical cannabinoid products, including a cannabidiol TPM soft-gel capsule in Phase III clinical trial for the treatment of insomnia; and non-antibiotic feed additive products to enhance feed efficiency and the health of livestock animals. The company was formerly known as Phosphagenics Limited and changed its name to Avecho Biotechnology Limited in May 2019. Avecho Biotechnology Limited was incorporated in 1992 and is based in Clayton, Australia.
Frequently asked questions
What sector does Avecho Biotechnology Limited (AVEFF) operate in?
Avecho Biotechnology Limited belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Avecho Biotechnology Limited (AVEFF) current stock price?
As of the latest data, Avecho Biotechnology Limited stock price is $0.00, with a previous close of $0.00.
What is Avecho Biotechnology Limited (AVEFF) current market capitalization?
Avecho Biotechnology Limited market cap is approximately 17.39 million.
What is Avecho Biotechnology Limited (AVEFF) EBITDA?
Avecho Biotechnology Limited EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -3.19 million.
Does Avecho Biotechnology Limited (AVEFF) pay dividends?
No. Avecho Biotechnology Limited does not pay a dividend.
What is Avecho Biotechnology Limited (AVEFF) beta (volatility) score?
Avecho Biotechnology Limited has a beta of 1.266, suggesting it is more volatile than the market.
